Design Therapeutics, Inc. (DSGN)
NASDAQ: DSGN · Real-Time Price · USD
3.620
+0.120 (3.43%)
At close: May 12, 2025, 4:00 PM
3.620
0.00 (0.00%)
After-hours: May 12, 2025, 4:00 PM EDT
Design Therapeutics Employees
Design Therapeutics had 54 employees as of December 31, 2024. The number of employees decreased by 4 or -6.90% compared to the previous year.
Employees
54
Change (1Y)
-4
Growth (1Y)
-6.90%
Revenue / Employee
n/a
Profits / Employee
-$1,040,704
Market Cap
204.93M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 54 | -4 | -6.90% |
Dec 31, 2023 | 58 | 0 | - |
Dec 31, 2022 | 58 | 20 | 52.63% |
Dec 31, 2021 | 38 | 23 | 153.33% |
Dec 31, 2020 | 15 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
DSGN News
- 5 days ago - Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 11 days ago - Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy - GlobeNewsWire
- 21 days ago - Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025 - GlobeNewsWire
- 25 days ago - Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer - GlobeNewsWire
- 2 months ago - Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 2 months ago - Design Therapeutics to Participate in Leerink's Global Healthcare Conference - GlobeNewsWire
- 6 months ago - Design Therapeutics to Participate in Multiple Upcoming Investor Conferences - GlobeNewsWire
- 6 months ago - Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio - GlobeNewsWire